Pfizer

Corporate/Government Newsroom
Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. We make medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world’s best-known consumer healthcare brands. Every day, our colleagues work in developed and emerging markets to treat, cure and eradicate life-threatening conditions and challenge some of the most feared diseases of our time. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, visit www.pfizer.com. Source

Actions

Share this page

Media Outlet details

Scope International
Language English
Country United States of America
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing

Recent Articles

Search

Pfizer Announces Chief Financial Officer Transition

| Pfizer
Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted.
Open in Who Shared View Duplicates (45) Issue with article?

Living Longer with Cancer: Redefining What It Means to Survive

| Pfizer
The sixth season of Science Will Win, Pfizer's award-winning podcast, focused on cancer. The six episodes explored the disease from every angle, from its rising incidence in younger populations to the precision medicine tools helping clinicians catch it earlier and treat it more effectively. Host Dr. Raven Baxter delved deep into each topic, interviewing doctors, scientists, researchers, and Pfizer colleagues to glean their insights and discuss the ongoing effort to conquer cancer.
Open in Who Shared Issue with article?

Pfizer's 2025 Impact Report Highlights Progress Across Patients, Planet, and Responsible Business

| Pfizer
Here at Pfizer, we are in the business of breakthroughs, and while our focus is on making advancements that impact patients’ lives, we are also aware of our work’s broader impact on the world. Every year, we take stock of the impact our work has on the world, the environment, and people themselves in our Impact Report.
Open in Who Shared Issue with article?

Multiple Myeloma: Shedding Light on a Rare but Complex Blood Cancer

| Pfizer
Donna is more than a cancer patient: Donna is a wife, mother, grandmother, sister, and friend who has a full life outside of treatment. Her journey with multiple myeloma has revealed depths of resilience and strength that have long served her in all of those roles. “We have multiple myeloma…but that should not define us,” Donna shared in a recent video interview.
Open in Who Shared Issue with article?

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

| Pfizer
Pfizer Inc. (NYSE: PFE)today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors.
Open in Who Shared Issue with article?

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

| Pfizer
Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA). The objectives for the Phase 2 studies were to identify the right doses for Phase 3 and to test escalation schemes.
Open in Who Shared Issue with article?

Menstrual Migraine Explained: Why They Happen and What Can Help

| Pfizer
For some people, migraine attacks aren’t random. Instead, they follow predictable hormonal rhythms that unfold over time. Menstrual migraine is a common type of migraine, yet it’s still a condition many aren’t familiar with.1 Compared with other types of migraine, menstrual-related migraine may cause more severe symptoms.1 Understanding how and why these migraine attacks occur can help you anticipate symptoms before they begin and work with your doctor to better manage them.
Open in Who Shared Issue with article?

Decoding the Complex Science of Obesity

| Pfizer
GLP-1. GIP. Amylin. Incretins. Peptides. NuSH. It’s not hard to see why the language surrounding modern obesity research sometimes feels like an alphabet soup of scientific terms. But behind each is a growing understanding of how the body regulates hunger, metabolism, energy use, and weight. It’s shaping what we know about how those systems might contribute to obesity.
Open in Who Shared Issue with article?

May Social Media Round-Up—ASCO, Q1 2026 Results, and More

| Pfizer
Summer’s approaching fast, but here at Pfizer the work doesn’t stop. So before you get outside to enjoy the warmer weather, catch up with the latest activity on our social channels. May has been chock full of highlights—from sharing the latest data across our cancer work at ASCO 2026 to a feature in TIME highlighting how we bring science from the lab to life, we’re offering looks behind the science of Pfizer’s research.
Open in Who Shared Issue with article?

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

| Pfizer
Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with or without bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
Open in Who Shared View Duplicates (58) Issue with article?

Pfizer Journalists

Julianelle, Michael
Neugebauer, Allison